Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Nexalin Technology, Inc.

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Closing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Unveils Next-Generation HALO™ Clarity
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
From Nexalin Technology, Inc.
Via GlobeNewswire
Tickers NXL NXLIW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.